サル痘治療の世界市場：市場規模 - 治療別、製品タイプ別、剤形別、投与経路別、年齢別、性別、処方タイプ別、エンドユーザー別、地域別展望、競合戦略、セグメント別予測（～2032年）

世界のサル痘治療の市場規模は、2032年までに2億3,000万米ドルに達し、CAGRで10.37%の成長が予測されています。世界のサル痘症例の増加が、市場の収益成長を促進する主な要因です。

当レポートでは、世界のサル痘治療市場について調査し、市場力学、市場変数と展望、治療・製品タイプ・剤形・投与経路・年齢・性・処方タイプ・エンドユーザー・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 イントロダクション

• 調査範囲
• 市場セグメント分析

第2章 調査手法

• 調査データソース
• 市場規模の推定
• データの三角測量

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因、抑制要因、機会、課題の分析
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
• 世界のサル痘治療市場におけるCOVID-19の影響

第5章 市場変数と展望

• SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
• PESTEL分析
  • 政治情勢
  • 経済情勢
  • 社会情勢
  • 技術情勢
  • 環境情勢
  • 法的情勢
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入者の脅威
  • 競合企業間の敵対関係
• ヒートマップ分析

第6章 競合情勢

• 世界のサル痘治療の製造拠点流通、販売エリア、製品タイプ
• 世界のサル痘治療市場における合併・買収、パートナーシップ、製品の発売、コラボレーション

第7章 世界のサル痘治療市場：治療別（2019年～2032年（100万米ドル））

• 薬物療法
  • 鎮痛剤
  • 鎮痒剤・かゆみ止め
  • 解熱鎮痛剤
  • 抗ウイルス剤
• ワクチン
  • 天然痘ワクチン
  • JYNNEOS/Imvanex
• ワクシニア免疫グロブリン（VIG）

第8章 世界のサル痘治療市場：製品タイプ別（2019年～2032年（100万米ドル））

• クリーム
• ジェル
• 注射剤
• 軟膏
• 錠剤

第9章 世界のサル痘治療市場：剤形別（2019年～2032年（100万米ドル））

• 液体
• 半固体
• 固体

第10章 世界のサル痘治療市場：投与経路別（2019年～2032年（100万米ドル））

• 経口
• 非経口
• 局所

第11章 世界のサル痘治療市場：年齢別（2019年～2032年（100万米ドル））

• 成人
• 老人
• 小児

第12章 世界のサル痘治療市場：性別（2019年～2032年（100万米ドル））

• 女性
• 男性
• その他

第13章 世界のサル痘治療市場：処方タイプ別（2019年～2032年（100万米ドル））

• OTC（一般用医薬品）
• Rx（処方箋医薬品）

第14章 世界のサル痘治療市場：エンドユーザー別（2019年～2032年（100万米ドル））

• 病院薬局
• オンライン薬局
• 小売薬局

第15章 世界のサル痘治療市場：地域別（2019年～2032年（100万米ドル））

• 世界のサル痘治療の規模・市場シェア：地域別（2019年～2025年）
• 世界のサル痘治療の規模・市場シェア：地域別（2026年～2032年）
• アジア太平洋
  • オーストラリア
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • その他の欧州
• 中東・アフリカ
  • サウジアラビア王国
  • アラブ首長国連邦
  • その他の中東・アフリカ
• 北米
  • カナダ
  • メキシコ
  • 米国
• ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • その他のラテンアメリカ

第16章 企業プロファイル

• Bavarian Nordic
  • 企業概要
  • 財務展望
  • 製品概要
  • 最近の開発
• Chimerix
• CIDIC Co., Ltd.
• EMERGENT
• Hetero
• Olon S.p.A
• Piramal Pharma Solutions
• SIGA Technologies
• Teva Pharmaceutical Industries Ltd.

第17章 略語一覧

第18章 参照リンク

第19章 結論

第20章 調査範囲

Global Monkeypox Treatment Market Overview

According to SPER Market Research, the Global Monkeypox Treatment Market is estimated to reach USD 0.23 billion by 2032 with a CAGR of 10.37%.

The monkeypox virus is the source of this uncommon but severe illness. Since monkey pox is a contagious disease, it can be spread by sick people, animals, or even contaminated objects. The monkeypox virus results in skin lesions and rashes on every part of the diseased body. Monkeypox symptoms and signs include fever, swollen lymph nodes, aches and chills, and muscle pain.

The market for monkeypox is anticipated to grow quickly in terms of CAGR. The increase in monkeypox cases worldwide is the main factor driving monkeypox market revenue growth.One of the main factors propelling the growth of the monkeypox market is the increase in monkeypox prevalence as a result of the rise in viral infections brought on by the monkeypox virus. The monkeypox virus can cause viral infection in people with weakened immune systems. Increase in numerous chronic illnesses and dermatological conditions like eczema, which causes weakened immunity and increases the risk of contracting the monkeypox virus, leads to the expansion of the monkeypox market.The market expansion of monkeypox treatments is supported by increased research and development for the treatment of monkeypox as well as rising global demand for the therapy.

Impact of COVID-19 on the Global Monkeypox Treatment Market

The recent COVID-19 pandemic has resulted in weakened immunity in those affected, which raises the risk of monkeypox virus infection. Monkeypox market expansion was boosted by a large population that was infected with COVID-19. Businesses across all industries are struggling financially as a result of the global lockdown caused by the corona virus (COVID-19) epidemic. Global supply chains and manufacturing operations have been affected as a result of lockdowns imposed by national authorities, travel restrictions, and other COVID-19 safety measures. However, the market for treating monkeypox is barely impacted by COVID-19.However, due to a significant lack of medical supplies and raw materials, manufacturing locations located in the worst-hit nations have been badly impacted. This has disrupted the world's supply chains.The Food and Drug Administration (FDA) of the United States is still keeping tabs on the supply chain. In order to improve the supply chain of medical products in the future, the Center for Drug Evaluation and Research (CDER) Drug Shortage Staff asked manufacturers to assess their entire supply chain of various products, including ethanol, EDTA (Ethylenediaminetetraacetic acid), and vaccine manufacturing equipment, among others.

Scope of the Report:

Report Metric Details

• Market size available for years: 2019-2032

• Base year considered: 2021

• Forecast period: 2022-2032

• Segments covered: By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User

• Regions covered: Asia Pacific, Europe, Middle East and Africa, North America, Latin America

• Companies Covered: Bavarian Nordic, Chimerix, CIDIC Co., Ltd., EMERGENT, Hetero, Olon S.p.A, Piramal Pharma Solutions, SIGA Technologies, Teva Pharmaceutical Industries Ltd.

Global Monkeypox Treatment Market Segmentation:

• By Treatment: Based on the Treatment, Global Monkeypox Treatment Market is segmented as; Medications (Analgesics, Antipruritic or Anti-itch drugs, Antipyretics, Antivirals), Vaccine (Smallpox Vaccine, JYNNEOS/Imvanex), Vaccinia Immune Globulin (VIG).

• By Product Type: Based on the Product Type, Global Monkeypox Treatment Market is segmented as; Creams, Gels, Injectable, Ointment, Tablets.

• By Dosage Form: Based on the Dosage Form, Global Monkeypox Treatment Market is segmented as; Liquid, Semi Solid, Solid.

• By Prescription Type: Based on the Prescription Type, Global Monkeypox Treatment Market is segmented as; Over the counter (OTC) drugs, Prescription (Rx) drugs.

• By End User: Based on the End User, Global Monkeypox Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

• By Region: Over the forecast period, the monkeypox market in Asia Pacific is anticipated to develop at the quickest rate. Other factors contributing to the market expansion in the region include an increase in the number of patients with monkeypox, government activities to raise public awareness, and an increase in demand for the treatment.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1 Research data source
  • 2.1.1 Secondary data
  • 2.1.2 Primary data
  • 2.1.3 SPER's internal database
  • 2.1.4 Premium insight from KOL's
• 2.2 Market size estimation
  • 2.2.1 Top-down and Bottom-up approach
• 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1 Drivers
  • 4.1.2 Restraints
  • 4.1.3 Opportunities
  • 4.1.4 Challenges
• 4.2. COVID-19 Impacts of the Global Monkeypox Treatment Market

5. Market variables and outlook

• 5.1. SWOT analysis
  • 5.1.1 Strengths
  • 5.1.2 Weaknesses
  • 5.1.3 Opportunities
  • 5.1.4 Threats
• 5.2. PESTEL analysis
  • 5.2.1 Political landscape
  • 5.2.2 Economic landscape
  • 5.2.3 Social landscape
  • 5.2.4 Technological landscape
  • 5.2.5 Environmental landscape
  • 5.2.6 Legal landscape
• 5.3. PORTER'S five forces analysis
  • 5.3.1 Bargaining power of suppliers
  • 5.3.2 Bargaining power of Buyers
  • 5.3.3 Threat of Substitute
  • 5.3.4 Threat of new entrant
  • 5.3.5 Competitive rivalry
• 5.4. Heat map analysis

6. Competitive Landscape

• 6.1 Global Monkeypox Treatment Manufacturing Base Distribution, Sales Area, Product Type
• 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Monkeypox Treatment Market

7. Global Monkeypox Treatment Market, By Treatment, 2019-2032 (USD Million)

• 7.1 Medications
  • 7.1.1 Analgesics
  • 7.1.2 Antipruritic or Anti-itch drugs
  • 7.1.3 Antipyretics
  • 7.1.4 Antivirals
• 7.2 Vaccine
  • 7.2.1 Smallpox Vaccine
  • 7.2.2 JYNNEOS/Imvanex
• 7.3 Vaccinia Immune Globulin (VIG)

8. Global Monkeypox Treatment Market, By Product Type, 2019-2032 (USD Million)

• 8.1 Creams
• 8.2 Gels
• 8.3 Injectable
• 8.4 Ointment
• 8.5 Tablets

9. Global Monkeypox Treatment Market, By Dosage Form, 2019-2032 (USD Million)

• 9.1 Liquid
• 9.2 Semi Solid
• 9.3 Solid

10. Global Monkeypox Treatment Market, By Route of Administration, 2019-2032 (USD Million)

• 10.1 Oral
• 10.2 Parenteral
• 10.3 Topical

11. Global Monkeypox Treatment Market, By Age, 2019-2032 (USD Million)

• 11.1 Adults
• 11.2 Geriatrics
• 11.3 Paediatrics

12. Global Monkeypox Treatment Market, By Gender, 2019-2032 (USD Million)

• 12.1 Female
• 12.2 Male
• 12.3 Others

13. Global Monkeypox Treatment Market, By Prescription Type, 2019-2032 (USD Million)

• 13.1 Over the counter (OTC) drugs
• 13.2 Prescription (Rx) drugs

14. Global Monkeypox Treatment Market, By End User, 2019-2032 (USD Million)

• 14.1 Hospital Pharmacy
• 14.2 Online Pharmacy
• 14.3 Retail Pharmacy

15. Global Monkeypox Treatment Market, By Region, 2019-2032 (USD Million)

• 15.1 Global Monkeypox TreatmentSize and Market Share by Region (2019-2025)
• 15.2 Global Monkeypox TreatmentSize and Market Share by Region (2026-2032)
• 15.3 Asia-Pacific
  • 15.3.1 Australia
  • 15.3.2 China
  • 15.3.3 India
  • 15.3.4 Japan
  • 15.3.5 South Korea
  • 15.3.6 Rest of Asia-Pacific
• 15.4 Europe
  • 15.4.1 France
  • 15.4.2 Germany
  • 15.4.3 Italy
  • 15.4.4 Spain
  • 15.4.5 United Kingdom
  • 15.4.6 Rest of Europe
• 15.5 Middle East & Africa
  • 15.5.1 Kingdom of Saudi Arabia
  • 15.5.2 United Arab Emirates
  • 15.5.3 Rest of Middle East & Africa
• 15.6 North America
  • 15.6.1 Canada
  • 15.6.2 Mexico
  • 15.6.3 United States
• 15.7 Latin America
  • 15.7.1 Argentina
  • 15.7.2 Brazil
  • 15.7.3 Rest of Latin America

16. Company Profiles

• 16.1 Bavarian Nordic
  • 16.1.1 Company details
  • 16.1.2 Financial outlook
  • 16.1.3 Product summary
  • 16.1.4 Recent developments
• 16.2 Chimerix
  • 16.2.1 Company details
  • 16.2.2 Financial outlook
  • 16.2.3 Product summary
  • 16.2.4 Recent developments
• 16.3 CIDIC Co., Ltd.
  • 16.3.1 Company details
  • 16.3.2 Financial outlook
  • 16.3.3 Product summary
  • 16.3.4 Recent developments
• 16.4 EMERGENT
  • 16.4.1 Company details
  • 16.4.2 Financial outlook
  • 16.4.3 Product summary
  • 16.4.4 Recent developments
• 16.5 Hetero
  • 16.5.1 Company details
  • 16.5.2 Financial outlook
  • 16.5.3 Product summary
  • 16.5.4 Recent developments
• 16.6 Olon S.p.A
  • 16.6.1 Company details
  • 16.6.2 Financial outlook
  • 16.6.3 Product summary
  • 16.6.4 Recent developments
• 16.7 Piramal Pharma Solutions
  • 16.7.1 Company details
  • 16.7.2 Financial outlook
  • 16.7.3 Product summary
  • 16.7.4 Recent developments
• 16.8 SIGA Technologies
  • 16.8.1 Company details
  • 16.8.2 Financial outlook
  • 16.8.3 Product summary
  • 16.8.4 Recent developments
• 16.9 Teva Pharmaceutical Industries Ltd.
  • 16.9.1 Company details
  • 16.9.2 Financial outlook
  • 16.9.3 Product summary
  • 16.9.4 Recent developments

17. List of Abbreviations

18. Reference Links

19. Conclusion

20. Research Scope